A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

Nature Genetics

Volumn 20, Issue 3, 1998, Pages 284-287

  Deeb, Samir S ^a   Fajas, Lluis ^b   Nemoto, Masami ^a   Pihlajamäki, Jussi ^c   Mykkänen, Leena ^c   Kuusisto, Johanna ^c   Laakso, Markku ^c   Fujimoto, Wilfred ^a   Auwerx, Johan ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INSTITUT PASTEUR DE LILLE   (France)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROLINE; TRANSCRIPTION FACTOR; CELL RECEPTOR; PRIMER DNA;

ADULT; AMINO ACID ANALYSIS; ARTICLE; BINDING AFFINITY; BODY MASS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN SENSITIVITY; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSACTIVATION; TRANSCRIPTION REGULATION; AGED; ALLELE; AMINO ACID SUBSTITUTION; FINLAND; GENE FREQUENCY; GENETIC VARIABILITY; GENETICS; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROMOTER REGION;

ADULT; AGED; ALLELES; AMINO ACID SUBSTITUTION; BASE SEQUENCE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; FEMALE; FINLAND; GENE FREQUENCY; GENOTYPE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; VARIATION (GENETICS);

EID: 0031595923     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/3099     Document Type: Article

References (30)

1. Tontonoz, P., Hu, E. & Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell 79, 1147-1156 (1994).
2. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I. & Spiegelman, B.M. mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224-1234 (1994).
3. Tontonoz, P. & Spiegelman, B.M. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ. Curr. Opin. Genet. Dev. 5, 571-576 (1995).
4. Fajas, L. et al. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 272, 18779-18789 (1997).
5. Werman, A. et al. Ligand-independent activation domain in the N terminus of peroxisome proliferator-artivated receptor γ (PPARγ). Differential activity of PARγ 1 and -2 isoforms and influence of insulin. J. Biol. Chem. 272, 20230-20235 (1997).
6. Vidal-Puig, A. et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99, 2416-2422 (1997).
7. Kahn, C.R. Diabetes. Causes of insulin resistance. Nature 373, 384-385 (1995).
8. Spiegelman, B.M. & Flier, J.S. Adipogenesis and obesity: rounding out the big picture. Cell 87, 377-389 (1996).
9. Auwerx, J., Martin, G., Guerre-Millo, M. & Staels, B. Transcription, adipocyte differentiation, and obesity. J. Mol. Med. 74, 347-352 (1996).
10. Hotamisligil, G.S., Shargill, N.S. & Spiegelman, B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
11. Kliewer, S.A. et al., A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83, 813-819 (1995).
12. Lehmann, J.M. et al., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270, 12953-12956 (1995).
13. Saltiel, A.R. & Olefsky, J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45, 1661-1669 (1996).
14. Bouchard, C. Genetics of obesity: an update on molecular markers. Int. J. Obes. Rel. Metab. Disord. 19, S10-S13 (1995).
15. Meirhaeghe, A. et al. A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Hum. Mol. Genet. 7, 435-440 (1998).
16. Laakso, M. et al. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in Finland. Diabetes Care 11, 449-463 (1988).
17. Fujimoto, W.Y., Bergstrom, R.W., Newell-Morris, L. & Leonetti, D.L. Nature and nurture in the etiology of type 2 diabetes mellitus in Japanese Americans. Diabetes Metab. Rev. 5, 607-625 (1989).
18. Schoonjans, K. et al. PPARα and PPARγ activators direct a distinct tissue specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15, 5336-5348 (1996).
19. Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M. & Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331, 1188-1193 (1994).
20. Burant, CF. et al. Troglitazone action in independent of adipose tissue. J. Clin. Invest. 100, 2900-2908 (1997).
21. Reaven, G.M. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
22. Chagnon, Y.C., Perusse, L. & Bouchard, C. The human obesity gene map: the 1997 update. Obesity Res. 6, 76-92 (1998).
23. Norman, R.A. et al. Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11q21-q22. Am. J. Hum. Genet. 60, 166-173 (1997).
24. Beamer, B.A. et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-γ (hPPAR γ) gene. Biochem. Biophys. Res. Commun. 233, 756-759 (1997).
25. Hanis, C.L. et al. A genome-wide search for human non-insulin-dependent (type2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nature Genet. 13, 161-166 (1996).
26. Mykkanen, L., Laakso, M., Uusitupa, M. & Pyörälä, K. Prevalence of diabetes and impaired glucose tolerance in elderly subjects and their association with obesity and family history of diabetes. Diabetes Care 13, 1099-1105 (1990).
27. Nevin, D., Deeb, S. & Brunzell, J. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arterioscler. Thromb. 14, 869-873 (1994).
28. Vu-Dac, N. et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 96, 741-750 (1995).
29. Fried, M.G. & Crothers, D.M. CAP and RNA polymerase interactions with the lac binding stoichiometry and long range effects. Nucleic Acids Res. 11, 141-158 (1983).
30. Mykkanen, L. et al. Is there a sex difference in the association of plasma insulin level and insulin sensitivity with serum lipids and lipoproteins? Metabolism 43, 523-528 (1994).